Literature DB >> 15223631

The expression of the aurora-A gene and its significance with tumorgenesis in non-Hodgkin's lymphoma.

Yoshihiro Yakushijin1, Makoto Hamada, Masaki Yasukawa.   

Abstract

Non-Hodgkin's lymphoma (NHL) has a wide biological heterogeneity with various cell origin and biological features. Recent WHO classification of lymphoid neoplasms gives importance to immunological and cytogenetic features in addition to morphologic aspects of tumors. Several investigators have performed NHL subclassification based on other biological features of tumor cells. It is extremely important to clarify the proliferation mechanism of tumor cells, and understanding this mechanism may provide insight not only into the biology of tumors but also into the treatment strategy for NHL. Therefore, research focused on the cell cycle is one of the major approaches to the biology and the oncogenesis of NHL. The Aurora kinase family recently identified from Drosophila melamogaster is believed to be an essential kinase involved in mitotic cell cycles. Several groups have reported that Aurora kinases are overexpressed in some solid tumors, suggesting that Aurora kinases may be involved in tumor survival and proliferation. Here, we focus on the role of Aurora-A kinase in the tumorgenesis of NHL using our recent research data, and discuss the possibility of Aurora-A as a new molecular target of NHL treatment. Copyright 2004 Taylor and Francis Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223631     DOI: 10.1080/10428190410001683615

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.

Authors:  Carla Casulo; Owen O'Connor; Andrei Shustov; Michelle Fanale; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lauren Pinter-Brown; Ranjani Advani; Steven Horwitz
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

2.  Differential expression of aurora-A kinase in T-cell lymphomas.

Authors:  Rashmi Kanagal-Shamanna; Norman L Lehman; James P O'Donnell; Megan S Lim; Daniel S Schultz; Dhananjay A Chitale; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Kedar V Inamdar
Journal:  Mod Pathol       Date:  2013-02-15       Impact factor: 7.842

Review 3.  The potential role of Aurora kinase inhibitors in haematological malignancies.

Authors:  Sherif S Farag
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

4.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Authors:  Paul M Barr; Hongli Li; Catherine Spier; Daruka Mahadevan; Michael LeBlanc; Mansoor Ul Haq; Bryan D Huber; Christopher R Flowers; Nina D Wagner-Johnston; Steven M Horwitz; Richard I Fisher; Bruce D Cheson; Sonali M Smith; Brad S Kahl; Nancy L Bartlett; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

5.  Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP as a transforming target of Aurora-A.

Authors:  Chang-Tze Ricky Yu; Jung-Mao Hsu; Yuan-Chii Gladys Lee; Ann-Ping Tsou; Chen-Kung Chou; Chi-Ying F Huang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

7.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

8.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 9.  From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Int J Hematol       Date:  2014-02-08       Impact factor: 2.490

10.  Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines.

Authors:  Cong Wang; Qin Yan; Minmin Hu; Di Qin; Zhenqing Feng
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.